XNAS · Healthcare · Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | 1.91 | 2.03 | +6.28% | $6.96B | ✅ Beat | -1.54% | -1.49% | — |
| 2026-02-10 | Q4 2025 | 1.83 | 1.86 | +1.64% | $7.92B | ✅ Beat | -1.27% | +5.46% | -1.37% |
| 2025-10-30 |
| Q3 2025 |
| 2.14 |
| 2.47 |
| +15.42% |
| $7.77B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | 1.95 | 2.01 | +3.08% | $7.08B | ✅ Beat | — | — | — |
| 2025-04-24 | Q1 2025 | 1.76 | 1.81 | +2.84% | $6.67B | ✅ Beat | — | — | — |
| 2025-02-11 | Q4 2024 | 1.70 | 1.90 | +11.76% | $7.57B | ✅ Beat | — | — | — |
| 2024-11-06 | Q3 2024 | 1.55 | 2.02 | +30.32% | $7.54B | ✅ Beat | — | — | — |
| 2024-08-08 | Q2 2024 | 1.60 | 2.01 | +25.62% | $6.95B | ✅ Beat | — | — | — |
Showing last 8 quarters.